SALT LAKE CITY, Aug. 08, 2024 (GLOBE NEWSWIRE) -- In a release issued under the same headline earlier today by Recursion (Nasdaq: RXRX), please note that in the first bullet under "Additional Corporate Updates", the company's conference call should have been mentioned as having already taken place earlier this morning, rather than coming up later this afternoon as previously stated. The corrected bullet should have read: L(earnings) Call: We will host a L(earnings) Call on Aug 8, 2024 at 8:30 am Eastern Tim ...

Recursion Pharmaceuticals (RXRX) came out with a quarterly loss of $0.40 per share versus the Zacks Consensus Estimate of a loss of $0.35. This compares to loss of $0.38 per share a year ago. These figures are adjusted for non-recurring items. This quarterly report represents an earnings surprise of -14.29%. A quarter ago, it was expected that this biotechnology company would post a loss of $0.43 per share when it actually produced a loss of $0.39, delivering a surprise of 9.30%. Over the last four quarters ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2024 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-40323 RECURSION PHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) Delaware 46-4099738 (State or other ...

EXHIBIT 2.1 TRANSACTION AGREEMENT by and between EXSCIENTIA PLC and RECURSION PHARMACEUTICALS, INC. Dated as of August 8, 2024 TABLE OF CONTENTS Page ARTICLE I THE TRANSACTION 2 Section 1.01 The Transaction 2 Section 1.02 Closing 2 Section 1.03 Delivery of Court Order 2 ARTICLE II TRANSFER OF SCHEME SHARES; DELIVERY OF EXCHANGE SHARES 3 Section 2.01 Transfer of Scheme Shares 3 Section 2.02 Delivery of Exchange Shares 5 Section 2.03 Company Long Term Incentive Awards 6 Section 2.04 Withholding Rights 9 Secti ...

Salt Lake City, Aug. 08, 2024 (GLOBE NEWSWIRE) -- Recursion (NASDAQ:RXRX), a leading clinical stage TechBio company decoding biology to industrialize drug discovery, will provide business updates and report its Q2 2024 financial results on Thursday, August 8, 2024, before the opening of the financial markets. Recursion will host a L(earnings) Call on August 8, 2024 at 8:30 am Eastern Time / 6:30 am Mountain Time, interacting with a broad public audience around notable business developments and offering oppo ...

Salt Lake City, Aug. 08, 2024 (GLOBE NEWSWIRE) -- Recursion (NASDAQ:RXRX), a leading clinical stage TechBio company decoding biology to industrialize drug discovery, will provide business updates and report its Q2 2024 financial results on Thursday, August 8, 2024, before the opening of the financial markets. Recursion will host a L(earnings) Call on August 8, 2024 at 8:30 am Eastern Time / 6:30 am Mountain Time, interacting with a broad public audience around notable business developments and offering oppo ...

It's likely to experience a lot of growth. As a young and innovative company that heavily emphasizes the "tech" portion of the term "biotech," Recursion Pharmaceuticals (RXRX -3.56%) is a classic contender for being the kind of stock that can turn investors into millionaires. It has flashy technology and pioneering drug development methods. But can those really drive returns on the scale needed to make a relatively small investment grow to be worth millions? Buckle up and get ready for some calculations, be ...

Recursion Pharmaceuticals (RXRX) ended the recent trading session at $8.19, demonstrating a -1.92% swing from the preceding day's closing price. The stock's change was less than the S&P 500's daily gain of 0.08%. Meanwhile, the Dow experienced a drop of 0.12%, and the technology-dominated Nasdaq saw an increase of 0.07%. Regarding the entire year, the Zacks Consensus Estimates forecast earnings of -$1.56 per share and revenue of $47.44 million, indicating changes of +1.27% and +6.43%, respectively, compared ...

There's a lot to like about the company using automation and artificial intelligence to improve the new drugdiscovery process. Recursion Pharmaceuticals (RXRX 3.73%) is a start-up biotech company with an important twist. It's using automation technology and artificial intelligence (AI) to industrialize new drug discovery. Why Recursion Pharmaceuticals looks like a good investment New drug candidates discovered by Recursion should also have a better chance at success in clinical trials because there's a lot ...

Amidst the artificial intelligence (AI) revolution and a rapidly shifting landscape in drug development, Recursion Pharmaceuticals (RXRX 8.85%) is aiming to position itself at the intersection of both big trends. While it isn't the only biotech exploring these rising opportunities, it just might be one of the few to have what's needed to succeed in such a dynamic time. The core problem Recursion seeks to solve is that the process of discovering and making new medicines is becoming slower and more costly ove ...